Boliden just dropped its Q3 2026 scorecard with record operating profit of SEK 4.9b, yet the stock closed at SEK 499.9 and has barely moved over the past week. The market looks calm. The results are not.
Investors are focusing on a metals producer that just printed one of its most profitable quarters while trading on a P/E of 9.9x and sitting well below a published discounted cash flow value near SEK 943. This appears to be a sentiment mismatch: the mood is cautious, while the earnings profile and valuation signal something very different.
Impressed by Boliden’s record profit and low P/E but unsure whether this is a one-off event or part of a broader opportunity set in quality cyclicals? Compare it with other producers on our 201 high quality undervalued stocks
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): SEK 30,442m vs. SEK 21,971m (up 38.5%)
- Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025): SEK 3,887m vs. SEK 2,293m (up 69.5%)
- Basic EPS (Earnings Per Share) (Q3 2026 vs Q3 2025): SEK 13.69 vs. SEK 8.07 (up 69.7%)
- Trailing 12-Month Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025): SEK 14,269m vs. SEK 8,051m (up 77.3%)
Earnings are one thing, but investors who care about what they are paying for Boliden focus on the cash that actually comes through the business. On Boliden's cash flows alone, the stock could be a striking 47% undervalued.
Boliden bull case: zinc platform starts to deliver
The optimistic script says higher zinc scale and better smelter performance should start to show up in real earnings power.
"The Odda zinc smelter expansion, which management expects to add about SEK 250 million of annual EBITDA once fully ramped under the market conditions referenced, provides scope for higher processing volumes and earnings contribution from zinc and by products."
Q3 points in that direction. Odda availability moved to about 50% for the quarter and 70% in September, with management calling out materially improved ramp up. That, together with strong sulfuric acid pricing adding about SEK 200m year on year, fed into record SEK 4.9b operating profit and SEK 1.1b free cash flow.
Boliden bear case: project and grade risks not cleared
The more cautious view argues that heavier gearing and operational hiccups could blunt the Nexa and copper growth story.
"Execution setbacks on large projects, such as slower than planned ramp up at the Odda roaster due to automation trips and conveyor failures, could delay expected EBITDA contributions from new capacity and leave Boliden carrying higher depreciation and financing costs without the intended uplift in earnings and margins."
Q3 shows this risk is reduced but not gone. Odda issues are described as largely fixed, yet availability is still below the 90% target. Aitik also faced downgraded copper grades due to waste dilution. With Nexa still pending and working capital set to rise in Q4, execution remains a live concern.
The price and this Narrative do not agree. → Uncover what this Narrative says Boliden is actually worth.
Hunt For Earnings Disconnects
Boliden shows how solid operational updates can coincide with a flat share price. The real opportunity is finding stocks that may not fully reflect changing business fundamentals.
- Company 1 - 21% below our estimate - uses artificial intelligence and integrations to convert larger healthcare managed services contracts into recurring work.
- Company 2 - 43% below our estimate - shifts its manufacturing toward higher value sterile injectables while expanding capacity for outsourced drug formulation work.
- Company 3 - 29% below our estimate - tightens focus on secured retail lending as digital tools raise business per employee and enable leaner branches.
Three companies from the same screener. Open all 201 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com